Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma

Frontiers in Oncology - Tập 12
Francesca Bonello1, Serena Rocchi2,3, Gregorio Barilà4, Michela Sandrone1, Marco Tallarico2,3, Elena Zamagni2,3, M Scaldaferri5, Susanna Vedovato4, Cecilia Bertiond5, Laura Pavan4, Sara Bringhen1, Francesco Cattel5, Renato Zambello4, Michèle Cavo2,3, Roberto Mina1
1SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
2Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy
3IRCCS – Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli, Bologna, Italy
4Department of Medicine (DIMED), Hematology and Clinical Immunology Section, Padova University School of Medicine, Padova, Italy
5S.C. Farmacia Ospedaliera, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy

Tóm tắt

BackgroundThe anti-CD38 monoclonal antibody daratumumab is the backbone of most anti-multiple myeloma (MM) regimens. To mitigate the risk of infusion-related reactions (IRRs), intravenous daratumumab administration requires 7 hours for the first infusion and 3.5-4 hours thereafter, thus making daratumumab-containing regimens burdensome for patients and health care resources. Preliminary data suggest that a rapid (90-minute) infusion of daratumumab is safe and does not increase IRRs. The rapid schedule was adopted by our centers since 2019.MethodsWe conducted an observational multi-center, real-life study to assess the safety of rapid daratumumab infusion protocol from the third administration in relapsed MM patients receiving daratumumab alone or in combination with lenalidomide-dexamethasone or bortezomib-dexamethasone. The primary endpoint was the safety of the rapid infusion protocol, particularly in terms of IRRs.ResultsA total of 134 MM patients were enrolled. IRRs occurred in 7 (5%) patients and were mostly mild (6/7 of grade 1-2), with only 1 patient experiencing a grade 3 IRR. Due to the IRRs, 5 (3.7%) patients discontinued the rapid infusions and resumed daratumumab at the standard infusion rate, while 1 patient permanently discontinued daratumumab. In 4/7 patients (57%), IRRs occurred while resuming rapid daratumumab infusions after a temporary interruption (2-4 months). No other adverse event was considered related to the rapid infusion protocol.ConclusionsOur findings confirmed the safety of rapid daratumumab infusions starting from the third administration. In case of prolonged daratumumab interruption, it is advisable to resume infusions at the standard rate (3.5 hours) before switching to the rapid infusion.

Từ khóa


Tài liệu tham khảo

Moreau, 2019, Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab Before and After Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study, Lancet, 394, 29, 10.1016/S0140-6736(19)31240-1

Facon, 2019, Daratumumab Plus Lenalidomide and Dexamethasone for Untreated Myeloma, N Engl J Med, 380, 10.1056/NEJMoa1817249

Mateos, 2018, Daratumumab Plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma, N Engl J Med, 378, 10.1056/NEJMoa1714678

Palumbo, 2016, Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma, N Engl J Med, 375, 10.1056/NEJMoa1606038

Dimopoulos, 2016, Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma, N Engl J Med, 375, 10.1056/NEJMoa1607751

Dimopoulos, 2020, Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma (CANDOR): Results From a Randomised, Multicentre, Open-Label, Phase 3 Study, Lancet, 396, 10.1016/S0140-6736(20)30734-0

van de Donk, 2018, CD38 Antibodies in Multiple Myeloma: Back to the Future, Blood, 131, 13, 10.1182/blood-2017-06-740944

Nooka, 2018, Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab, J Oncol Pract, 14, 10.1200/jop.18.00143

Barr, 2018, Ninety-Minute Daratumumab Infusion Is Safe in Multiple Myeloma, Leukemia, 32, 10.1038/s41375-018-0120-2

Hamadeh, 2020, Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol, Clin Lymphoma Myeloma Leuk, 20, 10.1016/J.CLML.2020.02.014

Gozzetti, 2020, Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients, Front Oncol, 10, 10.3389/fonc.2020.570187

Lombardi, 2021, Safety of Ninety-Minute Daratumumab Infusion, J Oncol Pharm Pract, 27, 10.1177/1078155220951231

Patel, 2021, Retrospective Review of Accelerated Daratumumab Administration, J Oncol Pharm Pract, 107815522110099, 10.1177/10781552211009967

Gordan, 2021, Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study, Drugs - Real World Outcomes, 8, 10.1007/s40801-020-00226-3

Voorhees, 2020, Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial, Blood, 136, 10.1182/blood.2020005288

Attardi, 2021, Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study, Clin Lymphoma Myeloma Leuk, 21, 10.1016/j.clml.2021.06.018

Mateos, 2020, Subcutaneous Versus Intravenous Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (COLUMBA): A Multicentre, Open-Label, Non-Inferiority, Randomised, Phase 3 Trial, Lancet Haematol, 7, 10.1016/S2352-3026(20)30070-3

Chari, 2021, Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients With Multiple Myeloma Across Lines of Therapy (PLEIADES): An Open-Label Phase II Study, Br J Haematol, 192, 10.1111/bjh.16980

Thông tin
Thông tin xuất bản

Frontiers in Oncology

Tập 12

Thông tin tác giả